A comprehensive autoantigen-ome of autoimmune liver diseases identified from dermatan sulfate affinity enrichment of liver tissue proteins

Wei Zhang¹, Jung-hyun Rho², Michael H. Roehrl³* and Julia Y. Wang⁴*

Abstract

Background: Autoimmune diseases result from aberrant immune attacks by the body itself. It is mysterious how autoantigens, a large cohort of seemingly unconnected molecules expressed in different parts of the body, can induce similar autoimmune responses. We have previously found that dermatan sulfate (DS) can form complexes with molecules of apoptotic cells and stimulate autoreactive CD5+ B cells to produce autoantibodies. Hence, autoantigenic molecules share a unique biochemical property in their affinity to DS. This study sought to further test this uniform principle of autoantigenicity.

Results: Proteomes were extracted from freshly collected mouse livers. They were loaded onto columns packed with DS-Sepharose resins. Proteins were eluted with step gradients of increasing salt strength. Proteins that bound to DS with weak, moderate, or strong affinity were eluted with 0.4, 0.6, and 1.0 M NaCl, respectively. After desalting, trypsin digestion, and gel electrophoresis, proteins were sequenced by mass spectrometry. To validate whether these proteins have been previously identified as autoantigens, an extensive literature search was conducted using the protein name or its alternative names as keywords. Of the 41 proteins identified from the strong DS-affinity fraction, 33 (80%) were verified autoantigens. Of the 46 proteins with moderate DS-affinity, 27 (59%) were verified autoantigens. Of the 125 proteins with weak DS-affinity, 44 (35%) were known autoantigens. Strikingly, these autoantigens fell into the classical autoantibody categories of autoimmune liver diseases: ANA (anti-nuclear autoantibodies), SMA (anti-smooth muscle autoantibodies), AMA (anti-mitochondrial autoantibodies), and LKM (liver-kidney microsomal autoantigens).

Conclusions: This study of DS-affinity enrichment of liver proteins establishes a comprehensive autoantigen-ome for autoimmune liver diseases, yielding 104 verified and 108 potential autoantigens. The liver autoantigen-ome sheds light on the molecular origins of autoimmune liver diseases and further supports the notion of a unifying biochemical principle of autoantigenicity.

Keywords: Autoantigen, Autoantibody, Autoimmune liver disease, Hepatitis
Background
The etiology of autoimmune diseases in general has remained a biomedical mystery. It is not clear how and why some molecules or tissue components of the body become a self-target of the immune defense system, whereas most do not. In previous studies, we demonstrated that certain molecules from dying cells have affinity to dermatan sulfate (DS), and that these molecules can form macromolecular complexes with DS to co-stimulate autoreactive CD5+ B cells to secrete autoantibodies [1]. Furthermore, we demonstrated that molecules with affinity to DS have a high propensity to be autoantigens (autoAg) [2]. We proposed a uniform principle of autoantigenicity that explains how a vast variety of seemingly unrelated molecules can become autoantigenic by means of a shared biochemical property. In this study, we sought to test this principle and to define the repertoire of possible autoantigens, i.e., the autoantigen-ome, in autoimmune liver diseases.

Autoimmune diseases of the liver occur when the body’s own immune system attacks the liver [3–5]. These diseases have different clinical patterns with regard to degree of severity and clinical course, but they all share one important feature, i.e., the liver being the target of an aberrant autoimmune attack by autoantibodies and/or autoreactive cells. Autoimmune liver diseases are typically chronic conditions, and patients may experience persistent or recurrent autoimmune insults to the liver, often without overt symptoms. As the autoimmune attack persists, liver tissue scarring leads to hepatic fibrosis; and as fibrosis progresses to cirrhosis, liver function is compromised. Ultimately, end-stage liver disease and liver failure may ensue, requiring organ transplantation.

Among autoimmune diseases of the liver, autoimmune hepatitis (AIH) [3], primary biliary cirrhosis (PBC) [4], and primary sclerosing cholangitis (PSC) [5] are the most prominent. In AIH, the immune system attacks the hepatocytes and causes chronic inflammation of the liver. About 70% of AIH patients are female. In PBC, the autoimmune reaction is directed at small biliary ducts inside the liver. In PSC, autoimmunity targets the larger extrahepatic bile ducts. Characteristic morphological patterns are chronic inflammation and a hepatic pattern of injury with prominent plasma cells in AIH, destruction of small intrahepatic bile ducts and canals of Hering in PBC, and periductal fibrosis and inflammation of the larger bile ducts, often along with inflammatory bowel disease, in PSC. Although most liver autoimmune diseases fall into these three categories, overlaps and other syndromes also occur.

Autoimmune liver diseases are typically associated with several classes of autoantibodies, including ANA, AMA, anti-SMA/anti-F-actin, anti-LKM, and others [6, 7]. For AIH and PBC, testing for liver-related autoantibodies is a prerequisite for diagnosis. For PSC, autoantibodies are frequently present but their diagnostic value has not been established. When diagnosed at an early stage, autoimmune hepatitis can be controlled by daily doses of steroids and other medicines that suppress inflammation. However, these treatments only suppress or slow down the overactive immune system, but cannot cure the disease. Understanding the molecular origins of autoimmune liver diseases is therefore crucial to finding more effective therapies.

Methods
DS-Sepharose resin synthesis
DS-Sepharose resins were prepared by coupling dermatan sulfate (DS; Sigma-Aldrich) to EAH Sepharose 4B resins (GE Healthcare). Sepharose resins (20 ml) were washed with distilled water and 0.5 M NaCl and then mixed with 100 mg of DS dissolved in 10 ml of 0.1 M MES buffer (pH 5.0). N-ethyl-N-(3-dimethylaminopropyl) carbodiimide hydrochloride (Sigma-Aldrich) was added to a final concentration of 0.1 M. The reaction proceeded at 25 °C for 24 h with end-over-end rotation. After the first 60 min, the pH of the reaction mixture was re-adjusted to 5.0. After the coupling, the resins were washed three times, each time with a low pH buffer (0.1 M acetate, 0.5 M NaCl, pH 5.0) and a high pH buffer (0.1 M Tris, 0.5 M NaCl, pH 8.0). The washed DS-Sepharose resins were suspended in 10 mM phosphate buffer (pH 7.4) and packed into a C16/20 column (GE Healthcare). The column was equilibrated with 10 mM phosphate buffer before use.

Mouse liver protein extraction
Livers were obtained from 5-month-old BALB/c female mice (Jackson Laboratory, Bar Harbor, Maine). The mouse tissue use was approved by the Institutional Animal Care and Use Committee (IACUC) of Brigham and Women’s Hospital (Boston, MA). All animal care was provided according to institutional, local, state, and federal regulations at the Brigham and Women’s Hospital research animal facility. A total of 20 mice were killed with CO2, their blood was removed through heart puncture, and their livers were collected immediately. Livers were cleaned by rinsing with phosphate buffered saline (PBS, pH 7.2) twice and then stored at 4 °C for 1 h, −20 °C for 2 h, and then −80 °C until further processing. Thawed livers were cut to small pieces and pressed through a cell strainer (Fisher Scientific). To remove red blood cells, the liver tissue was mixed with 10 ml of RBC (red blood cell) lysis buffer for 10 s. After centrifugation for 5 min, the supernatant was discarded. The liver tissue was mixed with 40 ml of RIPA lysis buffer (Sigma-Aldrich) and 4 tablets of protease inhibitor (Complete protease inhibitor cocktail, Sigma-Aldrich). The tissue mixture was sonicated for 10 min or until all tissue pieces appeared dissolved.
The mixture was centrifuged at 13,300 rpm for 20 min, and the supernatant that contains total soluble liver proteins was collected. Protein concentration was measured by the RC DC protein assay (Bio-Rad).

**DS-affinity fractionation**

Pilot affinity fractionations were performed in small centrifuge tubes. Aliquots of 2 ml resin were centrifuged to remove the storage buffer, and 0.5 ml of extracted liver proteins was added. The tube was mixed by rotating end-over-end at room temperature for 1 h to allow sufficient binding of proteins to DS-resin. The resin slush was centrifuged, and the supernatant containing unbound proteins was removed. The resins were washed 4 times with 1 ml of 0.2 M NaCl in 10 mM phosphate buffer to further remove unbound or poorly bound proteins. Proteins bound to DS with weak affinity were released from the resins by 0.4 M NaCl in PBS by rotating end-over-end at room temperature for 30 min, and the supernatant containing weak-binding proteins was recovered by centrifugation. The high-affinity proteins still bound to DS-resin were obtained by boiling the resins with 0.2 ml of SDS-PAGE sample buffer. Proteins in each fraction were assessed by 1D gel electrophoresis.

After the pilot assessment, fractionation of larger quantities of liver proteins was carried out by FPLC using a Biologic Duo-Flow System (Bio-Rad). Liver proteins were loaded into the DS-Sepharose column in 10 mM phosphate buffer at a rate of 1 mL/min. The column was washed with 20 mL of buffer A to remove unbound proteins. Proteins bound to DS resins with weak-to-strong affinity were eluted with a step-gradient of 0.2 M, 0.4 M, 0.6 M, and 1.0 M NaCl in 10 mM phosphate buffer, with each step being 40 ml. Elution was monitored by UV and conductivity detectors. All bound fractions were collected. Fractions were concentrated and desalted in Vivaspin centrifugal concentrators (MWCO 10 kDa, Sigma-Aldrich). Concentrated proteins were reconstituted in 10 mM phosphate buffer for further analysis.

**Protein sequencing by mass spectrometry**

Fractionated proteins with different affinities to DS were separated on 1D SDS PAGE in 4–12% NuPAGE Novex Bis-Tris gels (Invitrogen). Based on protein band intensity, the protein lane containing proteins eluting at 0.4 M NaCl was cut into 3 sections, containing top, middle, and bottom bands. The lanes containing proteins eluting at 0.6 M and 1.0 M NaCl were each cut into 2 sections, containing top and bottom bands, respectively. Gel sections were transferred into 1-ml tubes, cut into tiny pieces, dehydrated with acetonitrile, and then dried in a speed-vac. Proteins in gel pieces were then rehydrated in 50 mM NH₄HCO₃ and digested with 12.5 ng/µl modified sequencing-grade trypsin (Promega) at 4 °C overnight.

Mass spectrometric sequencing was performed at the Taplin Biological Mass Spectrometry Facility (Harvard Medical School, Boston, USA). Tryptic peptides were separated on a nano-scale C18 HPLC capillary column and analyzed after electrospray ionization in an LTQ linear ion-trap mass spectrometer (Thermo Scientific). Peptide sequences and protein identities were assigned by matching protein or translated nucleotide databases with the measured fragmentation pattern using Sequest software. Peptides were required to be fully tryptic peptides with XCorr values of at least 1.5 (+ 1 ion), 1.5 (+ 2 ion), or 3.0 (+ 3 ion). All data were manually inspected. Only proteins with at least 2 peptide matches were considered confidently identified.

**Results**

**Fractionation of liver proteins by DS-affinity**

Proteins extracted from mouse livers were separated into 4 fractions according to their strength of binding to DS: no-, weak-, medium-, and strong-affinity. This was carried out by loading the liver proteins onto DS-Sepharose columns to allow binding to take place. Proteins that did not bind to DS resins were washed off the column with the 10 mM phosphate loading buffer, followed by washing with 0.2 M NaCl and 10 mM phosphate buffer. Afterwards, proteins that had remained bound to DS were sequentially eluted from the column with 0.4 M, 0.6 M, and 1.0 M NaCl, designating these as weak-, medium-, and strong-affinity fractions, respectively. Elution was monitored for presence of proteins, and individual chromatographic fractions containing proteins at each of the salt strengths were pooled, desalted, and concentrated. Protein content and protein size distribution of the fractions were assessed with 1D SDS PAGE gels.

The majority of liver tissue proteins not binding to DS were observed in the flow-through, and non-specific binding proteins were further washed with 0.2 M NaCl. As the elution proceeded, the amount of proteins eluting at increasing ionic strength became smaller and smaller. Proteins eluting last off the column with 1.0 M NaCl had the highest affinity to DS but were also the relatively least abundant. The flow-through and 0.2 M NaCl washed proteins were not further analyzed. Proteins eluting at 0.4 M, 0.6 M, and 1.0 M salt were sequenced by LC-MS/MS, yielding 168, 68, and 41 identified protein entities, respectively. Some of the proteins were redundantly identified in 2 or 3 fractions and, when redundancies were excluded, the number of different uniquely identified proteins in the 0.4 M, 0.6 M, or 1.0 M fraction was found to be 125, 46, and 41, respectively.

**Proteins with strong DS-affinity eluting at 1.0 M ionic strength**

Proteins eluting off the DS-Sepharose column at 1.0 M NaCl were classified as having strong DS-affinity. From
the 1.0 M elution, 41 proteins were identified by MS sequencing (Table 1). A literature search revealed that at least 33 (80.5%) of these have previously been identified as autoantigens for autoantibodies. Furthermore, these autoantigens were not randomly distributed in functional attribution but fell nicely into 5 classical categories of autoantibodies in autoimmune liver diseases: ANA (anti-nuclear autoantibodies), SMA (smooth muscle autoantibodies), AMA (anti-mitochondrial autoantibodies), LKM (liver-kidney microsomal autoantigens), and peroxisome (Table 1).

Among the 41 proteins identified, 16 belong to the ANA family. They include 6 histones, 4 small nuclear ribonucleoproteins, 4 ribosomal proteins, and 2 others (polyadenylate-binding protein and barrier-to-autointegration factor). All of them are established ANA autoantigens (see references in Table 1). There are 5 proteins belonging to the SMA family, including spectrin alpha chain, myosin-9, myosin light chain, and lamin-A. All of them are known targets of autoantibodies (see references in Table 1). Among the AMA autoantigens, 7 were identified, with 4 having been verified as autoantigens, including Hspa5, Hspa9, glutamate dehydrogenase (Gld1), and apoptosis-inducing factor 1 (Aifm1). Autoantibodies to heat shock proteins (HSP) are widely found in autoimmune diseases as well as in numerous other diseases. Autoantibodies to HSP have been found in the circulation of various cancer patients, and are proposed as diagnostic and prognostic markers for various cancers such as breast cancer [40]. Autoantibodies to Gld1 have not been reported in humans but in mice and calves [27, 28]. Autoantibodies to Cpt2, Cps1, and Chdh could not be found in published reports. They could well represent autoantigens that have yet to be validated.

Autoantibodies to microsomal LKM antigens are associated with type 2 autoimmune hepatitis. Among proteins with high DS-affinity, 8 microsomal proteins were identified, including 3 of the UDG-glucuronosyltransferase family, 2 cytochromes, and 3 enzymes. Six of them (Ugt1a9, Ugt2b5, UgtCyb5, Cyb5, Pdia3, and Ces3) are known bona fide autoantigens (Table 1). Autoantibodies to Cox6c and Ass1 have not yet been described in literature. There are 5 proteins associated with the peroxisome in the 1.0 M elution fraction. Catalase and dipeptidyl peptidase (CD26, Dpp4) are reported autoantigens (Table 1). Autoantibodies to Acs11, Uox, and Decr2 have not yet been reported.

Proteins with moderate DS-affinity eluting at 0.6 M ionic strength
From fractions eluting at 0.6 M salt, 168 proteins were initially identified. Among these, 18 were also found in both 0.6 M and 1.0 M elution, including H2bj, H2afj, H2afy, Snrpb, Myh9, Lmna, Hspa9, Hspa5, Cps1, Cpt2, Gld1, Ugt2b5, Pdia3, Ass1, Acs11, Cat, Uox, and Aif. Among the rest, 3 (Sm D2, Spna2, and Ces) were found also in the 1.0 M elution but in not 0.6 M elution, and 22 proteins were found also in the 0.6 M but not in the 1.0 M elution. After excluding these redundancies, 125 proteins were found only in the 0.4 M elution (Table 3). As shown in Table 3, these 125 proteins fell naturally into 8 categories: ANA (10 proteins), SMA (15 proteins), AMA (35 proteins), LKM (10 proteins), peroxisome (6 proteins), apoptosis (4 proteins), proteasome (11 proteins), and miscellaneous (34 proteins).

The ANA autoantigens with weak DS-affinity are primarily isoforms of splicing factors and small nuclear ribonucleoproteins. Although autoantibodies to splicing factors have been reported [63], the exact isoforms
### Table 1 Liver proteins with strong DS-affinity

| # | Protein ID       | Gene name | Protein name                                      | Reference |
|---|------------------|-----------|--------------------------------------------------|-----------|
| 10 | IPI00329998.3    | H4        | Histone H4                                       | [8]       |
| 6  | IPI00114624.4    | Hist1h2bj | Histone H2B type 1-F/J/L                         | [9]       |
| 5  | IPI00153400.2    | H2afj     | Histone H2AJ                                      | [9]       |
| 5  | IPI00111957.3    | Hist1h2ba | Histone H2B type 1-A                             | [9]       |
| 4  | IPI00137852.5    | H2afy     | Core histone macro-H2A,1                         | [10]      |
| 2  | IPI00404590.1    | Hist1f0   | Histone H1.0                                      | [11]      |
| 3  | IPI00119220.1    | Snrpd2    | Small nuclear ribonucleoprotein Sm D2            | [12]      |
| 2  | IPI00114052.1    | Snrpb     | Small nuclear ribonucleoprotein-associated protein B | [13]      |
| 2  | IPI00122350.4    | Snrpa     | U1 small nuclear ribonucleoprotein A             | [14]      |
| 2  | IPI00133955.1    | Snrpe     | Small nuclear ribonucleoprotein E                | [15]      |
| 3  | IPI00131988.1    | Mrpflq    | 395 ribosomal protein L49, mitochondria          | [16]      |
| 3  | IPI003311236.1   | Rpl7      | 605 ribosomal protein L7                         | [17]      |
| 2  | IPI00122421.5    | Rpl27     | 605 ribosomal protein L27                        | [18]      |
| 2  | IPI00222549.6    | Rpl30     | 605 ribosomal protein L30                        | [16]      |
| 3  | IPI00124287.1    | Pabpc1    | Polyadenylate-binding protein                    | [19]      |
| 2  | IPI00119959.1    | Banf1     | Barrier-to-autointegration factor                | [20]      |
| 6  | IPI00753793.2    | Sna2      | Isoform 2 of Spectrin alpha chain                | [21]      |
| 5  | IPI00123181.4    | Myh9      | Myosin-9                                         | [22]      |
| 2  | IPI001090448.8   | G15Rik    | Myosin light chain, regulatory B-like            | [23]      |
| 2  | IPI00354819.5    | Myf6      | Isoform Smooth muscle of Myosin light chain 6    | [24]      |
| 2  | IPI00230435.1    | Lmna      | Isoform C2 of Lamin-A                           | [25]      |
| 13 | IPI00319992.1    | Hspa5     | 78 kDa glucose-regulated protein (Grp78)        | [26]      |
| 13 | IPI00114209.1    | Glud1     | Glutamate dehydrogenase 1, mitochondria          | [27, 28]  |
| 11 | IPI00134243.3    | Cpt2      | Carnitine O-palmitoyltransferase 2, mitochondria |           |
| 6  | IPI00133903.1    | Hsp9      | Stress-70 protein, mitochondria (Grp75)          | [29]      |
| 3  | IPI00111908.8    | Cps1      | Carbamoyl-phosphate synthase (ammonia), mitochondria |               |
| 3  | IPI00273146.1    | Chdh      | Choline dehydrogenase, mitochondria              |           |
| 2  | IPI00129577.1    | Aifm1     | Apoptosis-inducing factor 1 (Aif, Pdc8, programmed cell death protein), mitochondria | [30]      |
| 3  | IPI00111936.1    | Ugt1a9    | UDP-glucuronosyltransferase 1-9 (bilirubin-specific) |               |
| 3  | IPI00123232.2    | Ugt2b5    | UDP glucuronosyltransferase 2 family, polypeptide B5 |               |
| 2  | IPI00230113.5    | Cyb5      | Microsomal cytochrome b5                         | [33]      |
| 2  | IPI00131771.3    | Cox6c     | Cytochrome c oxidase subunit 6c                  |           |
| 2  | IPI00169666.3    | Ugt2b34   | UDP glucuronosyltransferase 2 family, polypeptide B3 |               |
| 2  | IPI00230108.6    | Pdia3     | Protein disulfide-isomerase A                     |           |
| 2  | IPI00134746.5    | Ass1      | Argininosuccinate synthase                       |           |
| 2  | IPI00387289.3    | Ces3      | Carboxylesterase                                 |           |
| 3  | IPI00112549.1    | Acsl1     | Long-chain-fatty-acid-CoA ligase                 |           |
| 2  | IPI00312085.8    | Cat       | Catalase                                         | [36, 37]  |
| 2  | IPI00233367.5    | Uox       | Uricase                                         |           |
| 2  | IPI00125325.1    | Decr2     | Peroxisomal 2,4-dienoyl-CoA reductase            |           |
| 2  | IPI00125813.1    | Dpp4      | Dipetidyl peptidase (CD26)                      | [38, 39]  |

*aColumns left to right: Number of peptides identified for the protein by mass spectrometry; Protein ID; Gene name; Protein name; Reference (if any) reporting autoantibodies induced by the protein*
## Table 2  Liver proteins with moderate DS-affinity

| Ref. | ANA (antinuclear autoantigens) |
|------|--------------------------|
| 8    | IPI00230730.4 Hist2h3b Histone H3.2 |
| 4    | IPI00223713.5 Hist1h1c Histone H1.2 |
| 2    | IPI00459318.1 Hist1h2bp Putative uncharacterized protein, histone |
| 2    | IPI00136632.3 H2afy3 Histone H2A member Y3 |
| 2    | IPI00320149.2 H2afv Histone H2A member V |
| 6    | IPI00308706.4 Rpl5 60S ribosomal protein L5 |
| 5    | IPI00127085.6 Rpl10a 60S ribosomal protein L10a |
| 3    | IPI00555113.2 Rpl18 60S ribosomal protein L18 |
| 3    | IPI00138892.2 Uba52 Ubiquitin-60S ribosomal protein L40 |
| 2    | IPI00122598.3 EG382723 Similar to ribosomal protein L10 |
| 5    | IPI00330964.8 Dkh9 Isomerase 2 of ATP-dependent RNA helicase, DNA helicase II |
| 4    | IPI00121596.3 Prp8 Pre-mRNA-processing-splicing factor 8 |
| 2    | IPI00109764.2 Top1 DNA topoisomerase 1 (Scl-70) |
| 2    | IPI00322749.3 Snrpd1 Small nuclear ribonucleoprotein Sm D1 |
| 2    | IPI00120162.1 Csk2a1 Casein kinase II subunit alpha |
| 6    | IPI00400300.1 Lmna Isoform C of Lamin-A |
| 4    | IPI00113861.1 Lmnrb2 Isoform B3 of Lamin-B |
| 2    | IPI00126191.5 Lmnrb2 Isoform B2 of Lamin-B |
| 2    | IPI00113824.1 Hspg2 Basement membrane-specific heparan sulfate proteoglycan core protein |
| 3    | IPI00315555.2 Bckdha Branched chain keto acid dehydrogenase E1, alpha polypeptide (mitochondrion matrix) |
| 5    | IPI0011877.1 Ssbp1 Single-stranded DNA-binding protein, mitochondria |
| 4    | IPI00153144.3 Suox Sulfite oxidase, mitochondria |
| 3    | IPI00133208.3 Hspa1l Heat shock 70 kDa protein 1L |
| 3    | IPI00323357.3 Hspa8 Heat shock cognate 71 kDa protein |
| 3    | IPI00420718.4 Hmargc2 Hydroxymethylglutaryl-CoA synthase, mitochondria |
| 3    | IPI0023092.5 Hadha Trifunctional enzyme subunit alpha, mitochondria |
| 3    | IPI00136511.1 Sks2a13 Calcium-binding mitochondrial carrier protein Aralar2 |
| 3    | IPI0011885.1 Uqrc1b Cytochrome b-c1 complex subunit 1, mitochondria |
| 3    | IPI00132799.4 C1qbp Complement component 1 q subcomponent binding protein |
| 2    | IPI00127941.3 Sks2a5 ADP/ATP translocase (mitochondrion inner membrane) |
| 2    | IPI00387397.9 Decr1 2,4-dienoyl-CoA reductase, mitochondria |
| 6    | IPI0017914.3 Arg1 Arginase-1 |
| 6    | IPI0015679.1 Ganab Isoform 2 of Neutral alpha-glucosidase A |
| 4    | IPI00621548.2 Por NADPH-cytochrome P450 reductase |
| 4    | IPI00134691.3 Ugt1a1 UDP-glucuronosyltransferase 1-1 |
| 2    | IPI0011055.6 Cyp2e1 Cytochrome P450 2E1 |
| 2    | IPI00321644.3 Cyp2d26 Cytochrome P450 2D26 (mouse) (LKM1 human) |
| 6    | IPI00127558.3 Acox1 Peroxisomal acyl-coenzyme A oxidase |
| 6    | IPI00127276.1 Ehhadh Enoyl-Coenzyme A hydratase/3-hydroxyacyl CoA dehydrogenase (peroxisomal bifunctional enzyme) |
| 2    | IPI00331628.5 Hsd17b4 Peroxisomal multifunctional enzyme type (17 beta-hydroxysteroid dehydrogenase type 4) |
identified here have not been reported. Anti-smooth muscle autoantigens identified in the 0.4 M NaCl elution included various forms of tropomyosin, actinin, fibronectin, actin, myosin, lamin, spectrin, and tubulin. Among the 15 identified here, 12 are bona fide autoantigens. Among the 35 proteins associated with mitochondria, 32 are enzymes, with 8/32 being reported autoantigens. These enzymes are from diverse families, e.g., dehydrogenases, synthases, acyltransferases, or carboxylases.

Similar to those identified in the 1.0 M and 0.6 M fractions, the LKM autoantigens included members of cytochrome and UDP-glucuronosyltransferase families. In addition, 3 unrelated proteins, Mttp, Aldh1l1, and Ces1 were identified. Ces1 is a verified autoantigen. Six enzymes associated with the peroxisome were identified. Thus far, only peroxisomal sarcosine oxidase has been described to be an autoantigen. In addition to the above autoantigen categories, additional proteins were found associated with apoptosis and the proteasome (Table 3). Annexin A6 and 14–3–3 proteins are reported autoantigens. Members of the proteasome have also been reported as autoantigens.

The remaining 34 proteins could not easily be classified into particular categories. The majority of them are not yet characterized as autoantigens. However, some are reported autoantigens, such as calreticulin, calnexin, catenin, protein disulfide-isomerase, peroxiredoxin 4, vitamin D-binding protein, and complement C3 (Table 3).

**Discussion**

Under normal physiologic conditions, the immune system is designed to protect from infection and disease through intricate mechanisms that distinguish self from non-self. It is a mystery why and how the immune system is mistakenly triggered to attack the body’s self. Autoimmune responses are causally linked to autoantibodies, autoreactive cells, or both. Despite advances in our understanding of the many facets of autoimmunity, the underlying molecular and cellular mechanisms that trigger autoimmunity remain largely unknown.

We are intrigued by the question why and how a vast number of diverse, seemingly functionally disconnected proteins in different parts of the body and with diverse structures and biological functions can all induce a converging autoimmune response, i.e., the production of autoantibodies by autoreactive B cells. Based on our previous studies [1, 2], we concluded that autoantigens share a common biochemical property in their binding affinity to dermatan sulfate (DS), also called chondroitin sulfate B, a glycosaminoglycan-type mucopolysaccharide found mostly in skin but also in blood vessels, heart valves, tendons, lungs, and other tissues. DS can directly bind molecules released from dying cells or other sources and form macromolecular DS-autoantigen complexes, and such complexes, in turn, can stimulate autoreactive B cells through simultaneous engagement of multiple signaling molecules on the B cell surface to induce an activated B cell response. To further characterize our proposed “unifying principle of autoantigenicity” based on DS-affinity as a shared physicochemical property of autoantigens, we tested whether we could identify autoantigens from a specific parenchymal organ, and whether autoantigens showed preferential intrinsic biochemical propensity for high DS-affinity.

Autoimmune liver diseases result from the immune system mistakenly attacking hepatocytes or cholangiocytes in the liver [3–5]. Patients with these chronic conditions are usually initially rather asymptomatic, and autoantibody serology tests are often necessary to clarify the diagnosis [6, 7]. For example, while routine blood tests for liver enzymes can reveal patterns of hepatitis, further autoantibody tests are needed to diagnose autoimmune hepatitis. Autoantibody tests also help distinguish autoimmune hepatitis from other liver diseases, such as viral hepatitis or metabolic diseases such as Wilson disease.

Common autoimmune liver diseases include autoimmune hepatitis (AIH) [3], primary biliary cirrhosis (PBC) [4], and primary sclerosing cholangitis (PSC) [5]. An autoimmune liver disease panel (a series of tests that detect autoantibodies to common autoantigens associated

---

**Table 2** Liver proteins with moderate DS-affinity (Continued)

| Protein ID | Gene name | Protein name | Reference (if any) reporting autoantibodies induced by the protein |
|------------|-----------|--------------|-----------------------------------------------------------------|
| 4 IPI001155996.6 | Hsd11b1 | Corticosteroid 11-beta-dehydrogenase isozyme | |
| 3 IPI00117705.1 | Ddost | Dolichyl-diphosphooligosaccharide-protein glycosyltransferase 48 kDa subunit | [62] |
| 3 IPI00313236.3 | Slc27a5 | Bile acyl-CoA synthetase | |
| 2 IPI00309035.2 | Rpn1 | Dolichyl-diphosphooligosaccharide-protein glycosyltransferase subunit 1 (ribophorin 1) | |
| 2 IPI00127016.1 | Hsd17b6 | Hydroxysteroid 17-beta dehydrogenase | [62] |
| 2 IPI00130985.1 | Rdh7 | Retinol dehydrogenase | |

*Columns left to right: Number of peptides identified for the protein by mass spectrometry; Protein ID; Gene name; Protein name; Reference (if any) reporting autoantibodies induced by the protein.*
### Table 3  Liver proteins with weak DS-affinity

| ANA (antinuclear autoantigens) | Ref. |
|-------------------------------|------|
| Sf3b3 | Isoform 1 of Splicing factor 3B subunit | [63] |
| Sfrs1 | Isoform 1 of Splicing factor, arginine/serine-rich | |
| Sfrs7 | Isoform 2 of Splicing factor, arginine/serine-rich | |
| Rpsa | 40S ribosomal protein SA | |
| Eftud2 | 116 kDa U5 small nuclear ribonucleoprotein component | [64] |
| Snrpa1 | U2 small nuclear ribonucleoprotein A | [65] |
| Snrpb | Small nuclear ribonucleoprotein-associated protein | [13] |
| Snrpd2 | Small nuclear ribonucleoprotein Sm D2 | [66] |
| Hnrnpf | Isoform 1 of Heterogeneous nuclear ribonucleoprotein F | |
| Rbm8a | Isoform 2 of RNA-binding protein 8 | |
| Tpm1 | Isoform 1 of Tropomyosin alpha-1 chain | [67] |
| Tpm3 | Tropomyosin 3, gamma | [68] |
| Tpm3 | Isoform 2 of Tropomyosin alpha-3 chain | |
| Tpm4 | Tropomyosin alpha-4 chain | [69] |
| Actn4 | Alpha-actinin | [70] |
| Fn1 | Fibronectin | [71] |
| Tubb2b | Tubulin beta-2B chain | [76] |
| Hsp90ab1 | MCG1823 | |
| Hsp90aa1 | Heat shock protein HSP 90-alpha | |
| Sardh | Sarcosine dehydrogenase, mitochondrial | |
| Atp5b | ATP synthase subunit beta, mitochondrial | [77] |
| Atp5a1 | ATP synthase subunit alpha, mitochondrial | |
| Ivd | Isovaleryl-CoA dehydrogenase, mitochondrial | |
| Dlst | Isoform 1 of Dihydrolipooyllysine-residue succinyltransferase component of 2-oxoglutarate dehydrogenase complex, mitochondrial | [78] |
| Dhtkd1 | Probable 2-oxoglutarate dehydrogenase E1 component DHTKD1, mitochondrial | |
| Dld | Dihydrolipoyl dehydrogenase | |
| Dbt | Lipoamide acyltransferase component of branched-chain alpha-keto acid dehydrogenase complex, mitochondrial | [78] |
| Dlat | Dihydrolipooyllysine-residue acetyltransferase component of pyruvate dehydrogenase complex, mitochondrial | |
| Aass | Alpha-aminoadipic semialdehyde synthase, mitochondrial | |
| Pccb | Propionyl-CoA carboxylase beta chain, mitochondrial | |
| Pcxa | Propionyl-CoA carboxylase alpha chain, mitochondrial | |
| Agmat | Agmatinase, mitochondrial | |
| Pcx | Pyruvate carboxylase, mitochondrial isoform 2 | |
| No. | IPI/OE/Ref. | Protein Name | Protein Description |
|-----|-------------|--------------|---------------------|
| 7   | IPI00111218.1 | Aldh2        | Alddehyde dehydrogenase, mitochondrial |
| 4   | IPI00226430.2 | Acaa2        | 3-Ketoacyl-CoA thiolase, mitochondrial |
| 3   | IPI00119766.1 | Rdh16        | Retinol dehydrogenase 1 |
| 3   | IPI00405699.2 | Aldh4a1      | Delta-1-pyrroline-5-carboxylate dehydrogenase, mitochondrial |
| 3   | IPI00121309.2 | Ndufs3       | NADH dehydrogenase [ubiquinone] iron-sulfur protein 3, mitochondrial |
| 3   | IPI00753303.2 | Npl22        | Dihydriodipicolinate synthase-like, mitochondrial |
| 3   | IPI00169862.1 | Coq9         | Ubiquinone biosynthesis protein COQ9, mitochondrial |
| 2   | IPI00323592.2 | Mdh2         | Malate dehydrogenase, mitochondrial |
| 2   | IPI00121105.2 | Hadh         | Hydroxacyl-Coenzyme A dehydrogenase, mitochondrial |
| 2   | IPI00459725.2 | Idh3a        | Isoform 1 of Isocitrate dehydrogenase [NAD] subunit alpha, mitochondrial |
| 2   | IPI00133553.1 | Mut          | Methylmalonyl-CoA mutase, mitochondrial |
| 2   | IPI00115607.3 | Hadhb        | Trifunctional enzyme subunit beta, mitochondrial |
| 2   | IPI00130804.1 | Ech1         | Delta(3,5)-Delta(2,4)-dienoyl-CoA isomerase, mitochondrial |
| 2   | IPI00469195.2 | Echdc2       | Isoform 1 of Enoyl-CoA hydratase domain-containing protein 2, mitochondrial |
| 2   | IPI00314909.2 | Agxt         | Alanine-glyoxylate aminotransferase |
| 2   | IPI00226140.5 | Maob         | Amine oxidase [flavin-containing] |
| 2   | IPI00121440.4 | Etfb         | Electron transfer flavoprotein subunit beta |
| 2   | IPI00454008.1 | Shmt2        | Serine hydroxymethyltransferase |
| 54  | IPI00309073.2 | Mttp         | Microsomal triglyceride transfer protein |
| 33  | IPI00153317.3 | Aldh11l      | 10-formyltetrahydrofolate dehydrogenase |
| 10  | IPI00111936.1 | Ugt1a9       | UDP-glucuronosyltransferase 1-9 |
| 8   | IPI00762897.2 | Ugcgl1       | UDP-glucoseglycoprotein glucosyltransferase |
| 3   | IPI00127233.3 | Ugt2b36      | UDP-glucuronosyltransferase |
| 3   | IPI00114778.1 | Cyp2c37      | Cytochrome P450 2C37 |
| 3   | IPI00131176.1 | Mt-Co2       | Cytochrome c oxidase subunit 2 |
| 2   | IPI00323908.1 | Cyp2d10      | Cytochrome P450 2D10 |
| 3   | IPI00331322.3 | Magt1        | Microsomal glutathione S-transferase |
| 9   | IPI00115867.4 | Ces1         | Liver carboxylesterase |
| 9   | IPI00310240.4 | Anxa6        | Annexin A6 isoform |
| 5   | IPI00116498.1 | Ywhaz        | 14-3-3 protein zeta/delta |
| 5   | IPI00118384.1 | Ywhae        | 14-3-3 protein epsilon |
| 5   | IPI00230707.6 | Ywhag        | 14-3-3 protein gamma |
| 8   | IPI00113845.1 | Psmb1        | Proteasome subunit beta type-1 |
| 4   | IPI00119239.2 | Psmb2        | Proteasome subunit beta type-6 |
| 3   | IPI00116712.1 | Psmb8        | Proteasome subunit beta type-8 |
Table 3 Liver proteins with weak DS-affinity (Continued)

|   | ANA (antinuclear autoantigens) | Ref. |
|---|---------------------------------|------|
| 2 | IP00128945.1 Psmb2 Proteasome subunit beta type-2 |
| 2 | IP00129512.3 Psmb4 Proteasome subunit beta type-4 |
| 2 | IP00136483.1 Psmb7 Proteasome subunit beta type-7 |
| 5 | IP00331644.5 Psma3 Proteasome subunit alpha type-3 | [88] |
| 4 | IP00109122.1 Psma8 Proteasome subunit alpha type-7-like |
| 4 | IP00131845.1 Psma6 Proteasome subunit alpha type-6 |
| 4 | IP00420745.7 Psma2 Proteasome subunit alpha type-2 |
| 4 | IP00277001.4 Psma4 Proteasome subunit alpha type-4 | [89] |
|   | Miscellaneous |      |
| 68 | IP00123639.1 Calr Calreticulin | [77] |
| 67 | IP00271951.5 Pdia4 Protein disulfide isomerase A |
| 61 | IP00122815.3 P4hb Protein disulfide-isomerase | [90] |
| 17 | IP00222496.3 Pdia6 Putative uncharacterized protein |
| 2 | IP00163011.2 Txndc5 Thioredoxin domain-containing protein |
| 20 | IP00119618.1 Canx Calnexin | [91] |
| 18 | IP0062235.5 Vcp Transitional endoplasmic reticulum ATPase | [92] |
| 14 | IP00125514.1 Entpd5 Ectonucleoside triphosphate diphosphohydrolase 5 |
| 11 | IP00475154.1 Rpn2 Dolichyl-diphosphooligosaccharide-protein glycosyltransferase subunit |
| 2 | IP0039035.2 Rpn1 Dolichyl-diphosphooligosaccharide–protein glycosyltransferase subunit |
| 11 | IP00112719.1 Alad Delta-aminolevulinic acid dehydratase |
| 10 | IP00115680.1 Prkcs Isoform 1 of Glucosidase 2 subunit beta |
| 7 | IP00119063.2 Lrp1 Pro-low-density lipoprotein receptor-related protein (alpha-2-macroglobulin receptor, apolipoprotein E receptor) |
| 2 | IP00624663.3 Pzip Alpha-2-macroglobulin |
| 7 | IP00135512.1 Cnpy2 Protein canopy homolog 2 |
| 6 | IP00316314.1 Hac1l 2-hydroxyacyl-CoA lyase |
| 6 | IP00116254.1 Prdx4 Peroxiredoxin-4 | [93] |
| 6 | IP00125899.1 Ctnnb1 Catenin beta-1 |
| 4 | IP00112963.1 Ctnna1 Catenin alpha-1 | [94] |
| 5 | IP00113869.1 Bsg Isoform 2 of Basigin (M6, EMMPRIN, TCSF, CD147) |
| 4 | IP00126184.7 Gc Vitamin D-binding protein |
| 4 | IP00123342.4 Hyou1 Hypoxia up-regulated protein |
| 3 | IP00130950.1 Bhmt Betaine–homocysteine S-methyltransferase |
| 3 | IP00134058.3 Erp44 Endoplasmic reticulum resident protein ERP44 |
| 3 | IP00387282.4 Aadac Arylacetamide deacetylase |
| 3 | IP00122346.2 Ssr4 Signal sequence receptor, delta |
| 3 | IP00317740.5 Gnbp2l1 Guanine nucleotide-binding protein subunit beta-2-like |
| 3 | IP00319973.3 Pgrmc1 Membrane-associated progesterone receptor component |
| 2 | IP00279218.1 Apeh Isoform 2 of Acylamo-noacid-releasing enzyme |
| 2 | IP00323624.3 C3 Isoform Long of Complement C3 | [97] |
| 2 | IP00116432.1 Fmo1 Dimethylamine monoxygenase [N-oxide-forming] |
| 2 | IP00114044.1 Man2a1 Alpha-mannosidase |
| 2 | IP00312018.6 Miec Malectin |
| 2 | IP00115241.1 Mup4 Major urinary protein 4 |

*Columns left to right: Number of peptides identified for the protein by mass spectrometry; Protein ID; Gene name; Protein name; Reference (if any) reporting autoantibodies induced by the protein.
with these diseases) include anti-liver-kidney microsomal antibodies (LKM), anti-mitochondrial antibodies (AMA), anti-nuclear antibodies (ANA), and anti-smooth muscle antibodies (SMA). AIH is further classified to two types, type I is defined by positive ANA and SMA, whereas type 2 is associated with anti-KLM autoantibodies. ANA occur in a wide variety of systemic autoimmune diseases, such as systemic lupus erythematosus, rheumatoid arthritis, Sjögren syndrome, and systemic sclerosis. Lupus hepatitis is regarded as a distinct manifestation of SLE [98]. The identification of 41 confirmed or putative ANA autoantigens from liver tissue uncovered by our study may perhaps explain the overlap autoantibody profile and clinical manifestations between lupus and AIH. AMA are hallmark diagnostic markers for PBC. In PBC, the targets are small bile ducts, but the prototypic serologic response is the production of a multilineage immune response to mitochondrial autoantigens. AMA are detected in 90–95% of PBC patients, although their presence is extremely low in the general population (varying between 0.16 and 1%) [99]. More than 60 autoantibodies have been detected in patients with PBC [99]. In our current study, we identified 54 verified and putative autoantigens associated with mitochondria.

Based on all of our observation so far, we find that autoantigens with the strongest DS affinity are typically DNA- and RNA-binding proteins. Other autoantigens largely display moderate to weak DS affinity. However, it should be noted that our definition of DS binding strength is arbitrary, with DS-autoAg complexes dissociable at 1.0, 0.6, and 0.4 M ionic strength defined as strongly, moderately, and weakly binding, respectively. All of these DS-binding proteins would be expected to remain in complexed forms with DS under physiologic conditions. For example, cytochrome P450 2D6 (CYP2D6) is the major autoantigen of LKM1 autoantibodies [100], but its mouse homologues (Cyp2d26 and Cyp2d10) were found to possess only moderate to weak DS affinity (Tables 2 and 3). As another example, PDC-E2 is a major autoantigen in PBC patients, but several components of the PDC (pyruvate dehydrogenase complex) were only identified in the weak but not the strong DS affinity fraction of this study (Table 3). Hence, these results suggest that proteins only need to exhibit some (sufficient) DS affinity to become potentially autoantigenic. It is also possible that in toto weakly DS-binding proteins may contain fragment epitopes with strong DS affinity, and such epitopes could determine the autoantigenicity of the protein.

The liver is the largest internal organ, the largest gland of the human body, and also the largest reservoir of human proteins. The liver serves hundreds of physiological functions, including removal of toxic substance, storage of glycogen, decomposition of red blood cells, production of bile and hormones, and synthesis of plasma proteins. Transcriptome analysis shows that 59% (n = 11,553) of all human proteins (n = 19,613) are expressed in the liver (The Human Protein Atlas). It should be noted that our DS-affinity approach provided a significant enrichment of liver protein autoantigens, yielding only a little over 200 proteins (i.e., around 1% of the total human proteome) as bona fide verified or potential autoantigens.

**Conclusions**

Our study of DS-affinity enrichment of the liver proteome produced a comprehensive autoantigen-ome that includes 104 bona fide autoantigens and 108 potential autoantigens for autoimmune liver diseases. These autoantigens fell into the classical categories of autoantibodies for autoimmune liver diseases. Our study provides further support to a model in which DS-affinity is a distinct biochemical property characterizing (a small subset of) human proteins (estimated at ~1%) that can become human autoantigens, whereas the majority of proteins (estimated at ~99%) that lack binding affinity have a much lower propensity to become targets of autoimmunity.

**Fig. 1** Model illustrating our hypothesis that binding affinity to dermatan sulfate is a distinct biochemical property characterizing (a small subset of) human proteins (estimated at ~1%) that can become human autoantigens, whereas the majority of proteins (estimated at ~99%) that lack binding affinity have a much lower propensity to become targets of autoimmunity.
biochemical property of proteins that can become autoantigens, whereas proteins that lack DS-affinity have a much lower propensity to be targets of autoimmunity (Fig. 1). These results may help in the further characterization of autoantigenic molecules and thus point to new innovative directions in autoimmunity research.

**Abbreviations**
AIH: Autoimmune hepatitis; AMA: Anti mitochondrial autoantibodies; DS: Dermatan sulfate; LKM: Liver-kidney microsomal autoantigens; PBC: Primary biliary cirrhosis; PSC: Primary sclerosing cholangitis; SMA: Smooth muscle autoantibodies

**Acknowledgements**
We thank the Taplin Biological Mass Spectrometry facility at Harvard Medical School for expert help with protein sequencing. We thank Michael W. Roehl for editing the manuscript.

**Authors’ contributions**
WZ carried out the experiments, analyzed the data, and reviewed the manuscript. JHR assisted in experiments and reviewed the manuscript. MHR consulted on the study, evaluated data, and edited the manuscript. JWY directed the study, analyzed data, conducted literature searches, and wrote the manuscript. All authors have read and approved the final manuscript.

**Funding**
This study was partially funded by the NIH (R01 AI068826 to JYW) and Curandis. The funding bodies were not involved in the design of the study and the collection, analysis, and interpretation of data and in writing the manuscript.

**Availability of data and materials**
All data generated or analyzed during this study are included in this published article.

**Ethics approval and consent to participate**
The mouse tissue use was approved by the Institutional Animal Care and Use Committee (IACUC) of Brigham and Women’s Hospital (Boston, MA). All animal care was provided according to institutional, local, state, and federal regulations at the Brigham and Women’s Hospital research animal facility.

**Consent for publication**
Not applicable.

**Competing interests**
WZ and JHR were supported by the NIH during the course of this study and declare no competing interests. MP Biomedical is the current employer of JHR and has neither relation to nor made contribution to the study and has not had any role in this research. MHR declares no competing interests. JWY is a co-founder and shareholder of Curandis and declares no other competing interests.

**Author details**
1Department of Gastroenterology, Affiliated Hospital of Guizhou Medical University, Guiyang, Guizhou, China. 2MP Bioc hemicals, Auckland, New Zealand. 3Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, USA. 4Curandis, New York, USA.

**Received: 6 December 2018 Accepted: 19 June 2019 Published online: 26 June 2019**

**References**
1. Wang JY, Lee J, Yan M, Rho JH, Roehl MH. Dermatan sulfate interacts with dead cells and regulates CDS4-B cell fate: implications for a key role in autoimmunity. Am J Pathol. 2011;178(3):2168–76.
2. Rho JH, Zhang W, Murali M, Roehl MH, Wang JY. Human proteins with affinity for dermatan sulfate have the propensity to become autoantigens. Am J Pathol. 2011;178(5):2177–90.
3. Terzilli Beretta-Piccoli B, Mieli-Vergani G, Vergani D. Autoimmune hepatitis: standard treatment and systematic review of alternative treatments. World J Gastroenterol. 2017;23(33):6030–48.
4. Trivedi HD, Lizaola B, Tapper EB, Bonder A. Primary biliary cholangitis: new treatments for an old disease. Frontline Gastroenterol. 2017;8(1):29–36.
5. Andrdz K, Hirschfield GM. Primary sclerosing cholangitis and the management of uncertainty and complexity. Frontline Gastroenterol. 2017;8(4):260–6.
6. Sebode M, Weller-Normann C, Liveriński T, Schramm C. Autoantibodies in autoimmune liver disease-clinical and diagnostic relevance. Front Immunol. 2018;9:609.
7. Toh BH. Diagnostic autoantibodies for autoimmune liver diseases. Clin Transl Immunology. 2017;6(5):e138.
8. Decker J, Boreen JH, Bakker M, Bird MP, Muller S, Voll R, Sjowall C, Hermann M, Hilbrands LB, van der Vlag J. Autoantibodies against modified histone peptides in SLE patients are associated with disease activity and lupus nephritis. PLoS One. 2016;11(10):e0165373.
9. Burlingame RW, Rubin RL. Autoantibody to the nucleosome subunit (H2A-H2B)-DNA is an early and ubiquitous feature of lupus-like conditions. Mol Biol Rep. 1996;23(3–4):159–66.
10. Kwon YS, Chung J, Shin GT, Lee SY, Jang YJ. Variable region genes of human monoclonal autoantibodies to histones H2A and H2B from a systemic lupus erythematosus patient. Mol Immunol. 2005;42(3):311–7.
11. Wiesierska-Gadek J, Penner E, Lindner H, Hetchman E, Sauermann G. Autoantibodies against different histone H1 subtypes in systemic lupus erythematosus sera. Arthritis Rheum. 1990;33(8):1273–8.
12. McClain MT, Ramsland PA, Kaufman KM, James JA. Anti-sm autoantibodies in systemic lupus target highly basic surface structures of complexed spirochetal autoantigens. J Immunol. 2002;168(4):2054–62.
13. Wang H, Demirkiran G, Bian X, Wallstrom G, Barker K, Karihikeyan K, Tang Y, Pasha SF, Leighton JA, Qi J, et al. Identification of antibody against SNRPB, small nuclear ribonucleoprotein-associated proteins B and G, as an autoantibody marker in Crohn’s disease using an Immunoproteomics approach. J Crohns Colitis. 2017;11(7):e488–56.
14. Mela A, Somarelli AJ, Wu W, Martinez L, Blom MB, Greidinger EL, Herrera RI. Differential immunoglobulin class-mediated responses to components of the U1 small nuclear ribonucleoprotein particle in systemic lupus erythematosus and mixed connective tissue disease. Lupus. 2013;22(13):1371–81.
15. Reuter R, Rothe S, Habets W, Van Vrenooij WJ, Luhmann R. Autoantibody production against the U1 small nuclear ribonucleoprotein particle proteins E, F, and G in patients with connective tissue diseases. Eur J Immunol. 1990;20(2):437–40.
16. Abi M, van Vergepe JM, Marzouki A, Giraud F, Rigal D, Reboud AM, Reboud JP, Monier JC. Heterogeneity of ribosomal autoantibodies from human, murine and canine connective tissue diseases. Immunol Lett. 1989;23(1):35–41.
17. Neu E, von Mikecz AH, Hemmerich PH, Peter HH, Fricke M, Deicher H, Genth E, Krainik U. Autoantibodies against eukaryotic protein L7 in patients suffering from systemic lupus erythematosus and progressive systemic sclerosis: frequency and correlation with clinical, serological and genetic parameters. The SLE study group. Clin Exp Immunol. 1995;100(2):198–204.
18. Perone D, Santos MA, Peixoto MS, Ciacarelli RM. Trypanosoma cruzi anti-dsDNA, anti-Sm and anti-RNP antibodies in a group of healthy blood donors. J Autoimmun. 1996;6(3):77–83.
19. Becker A, Ludwig N, Keller A, Rackenberg B, Eilenberger C, Oertel WH, Fassbender K, Meese E, Ruprecht K. Myasthenia gravis: analysis of serum autoantibody reactivities to 1827 potential human autoantigen proteins by protein microarrays. PLoS One. 2013;8(3):e58095.
20. Forne I, Carrascal M, Martinez-Lostao L, Abian J, Rodriguez-Sanchez JL, Juarez C. Identification of the autoantigen HB as the barrier-to-autointegration factor. J Biol Chem. 2003;278(50):50641–4.
21. Azzah MR, Azila MN, Zulkifli MN, Norita TY. The prevalence of antinuclear, anti-dsDNA, anti-Sm and anti-RNP antibodies in a group of healthy blood donors. Asian Pac J Allergy Immunol. 1996;14(2):125–8.
22. Migliorini P, Baldini C, Rocchi V, Bombardieri S. Anti-Sm and anti-RNP antibodies. Autoimmunity. 2005;38(1):147–54.
23. Bledzhyants DA, Muratov RM, Movsesyan RR, Podlubnaya ZA. Autoantibodies to myosin light chains in the blood as early marker of myocardial injury after aortocoronary bypass surgery. Bull Exp Biol Med. 2007;144(2):241–5.
24. Latif N, Baker CS, Dunn MJ, Rose ML, Brady P, Yazbou MC. Frequency and specificity of antihist antibodies in patients with dilated cardiomyopathy...
detected using SDS-PAGE and western blotting. J Am Coll Cardiol. 1993; 22(5):1378–84.

25. Malka D, Pham BN, Couvralin JC, Cortic M, Pessayre D, Efiringer S. Acute hepatitis caused by alveire associated with anti-Lamin a and C autoantibodies. J Hepatol. 1997;27(2):399–403.

26. Kadarm KM, Mande PV, Gaweis N, Ahire S, Khole LV. Autoantibodies to heat-shock protein, HSP65, and epitope spreading: high-dose dexamethasone therapy rescues ovarian function in experimental autoimmune ovum insufficiency mouse model. Am J Reprod Immunol. 2016;75(5):580–93.

27. Toivola DM, Habtezion A, Misiorek JO, Zhang L, Nystrom JH, Sharpe O, Robinson WH, Kwan R, Omary MB. Absence of keratin 8 or 18 promotes antimitochondrial autoantibody formation in aging male mice. FASEB J. 2015;29(12):5081–9.

28. Mayasari N, Van Knebel AT, de Vries RG, Kemp B, Parmentier HK. Natural autoantibodies in Bos taurus calves during the first twelve weeks of life. Vet Immunol Immunopathol. 2016;178:70–8.

29. Okubo M, Yamamoto K, Kato T, Matsuura N, Nishimaki T, Kusakawa R, To K, Muzumura Y, Nishioka K. Detection and epitope analysis of autoantigen-reactive T cells to the U1-small nuclear ribonucleoprotein A protein in autoimmune disease patients. J Immunol. 1993;151(2):1108–15.

30. Li L, Chen SH, Yu CH, Li YM, Wang SQ. Identification of hepatocellular carcinoma-associated antigens and autoantibodies by serological proteome analysis combined with protein microarray. J Proteome Res. 2008;7(2):611–20.

31. Manns MP, Obermayer-Stauber P. Cytochromes P450 and uridine triphosphatase-glucuronosyltransferases: model autoantigens to study drug-induced, virus-induced, and autoimmune liver disease. Hepatology. 1997;26(4):1054–66.

32. Obermayer-Stauber P, Manns MP. Cytochromes P450 and UDP-glucuronosyltransferases as hepatoctyal autoantigens. Baillieres Clin Gastroenterol. 1996;10(3):501–32.

33. Hao S, Fu R, Wang H, Shao Z. Screening novel autoantigens targeted by anti-Lamin a and C autoantibodies in patients with lupus erythematosus, as measured by monoclonal antibodies. Proc Natl Acad Sci U S A. 1986;83(22):8689–93.

34. Habets WJ, de Rooij DJ, Hoet MH, van de Putte LB, van Venrooij WJ. Demonstration of autoantibodies to recombinant human sulfite oxidase in patients with chronic liver disorders and analysis of their clinical relevance. Clin Exp Immunol. 2007;150(2):312–21.

35. Zieve GW, Khasial PR. The anti-Sm immune response in autoimmune and cell biology. Autoimmun Rev. 2003;2(5):235–40.

36. Jaekel HP, Klupsch T, Benkenstein B, Grobe N, Baldauf A, Schoessler W, Werle E. Reactivities to the Sm autoantigenic complex and the synthetic SmD1-aas83-119 peptide in systemic lupus erythematosus and other autoimmune diseases. J Autoimmun. 2001;17(4):347–54.

37. Kadam KM, Mande PV, Gawas N, Ahire S, Khole LV. Autoantibodies to heat-shock protein, HSPA5, and epitope spreading: high-dose dexamethasone therapy rescues ovarian function in experimental autoimmune ovum insufficiency mouse model. Am J Reprod Immunol. 2016;75(5):580–93.

38. Habets WJ, de Rooij DJ, Hoet MH, van de Putte LB, van Venrooij WJ. Demonstration of autoantibodies to recombinant human sulfite oxidase in patients with chronic liver disorders and analysis of their clinical relevance. Clin Exp Immunol. 2007;150(2):312–21.

39. Vojdani A, Bazargan M, Vojdani E, Samadi J, Nourian AA, Eghbalieh N, Vojdani A. Autoantibodies to heat-shock protein autoantibody profiling in breast cancer using customized protein microarray. Anal Bioanal Chem. 2016;408(5):1497–506.

40. D’Souza A, Kurien BT, Rodgers R, Shenoi J, Kurono S, Matsumoto H, Hensley JY, Cho EW. Identification of anti-SF3B1 autoantibody as a diagnostic marker in patients with lupus erythematosus, as measured by monoclonal antibodies. Proc Natl Acad Sci U S A. 1986;83(22):8689–93.

41. Fillit H, Shibata S, Sasaki T, Spera H, Kerr LD, Blake M. Autoantibodies to the protein core of vascular basement membrane heparan sulfate proteoglycan in systemic lupus erythematosus. Autoimmunity. 1993;14(3):243–45.

42. Preuss B, Berg C, Altenberend F, Gregor M, Stevanovic S, Klein R. Demonstration of autoantibodies in patients with unexplained infertility and premature ovarian failure. Fertil Steril. 2010;94(7):2041–46.

43. Kaburaki J, Stollar BD. Identification of human anti-DNA, anti-RNP, anti-SM, and anti-SS-A serum antibodies bearing the cross-reactive 16/6 idiotype. J Immunol. 1987;139(2):385–92.

44. Konikoff F, Swissa M, Shoenfeld Y. Autoantibodies to histones and their disease relevance. Clin Exp Immunol. 2007;150(2):312–21.

45. Cooper EL. Heat shock protein and gliadin peptide promote development of autoimmune disease. Clin Diagn Lab Immunol. 2004;11(3):515–24.

46. Mjelle JE, Rekvig OP, Fenton KA. Nucleosomes possess a high affinity for 4-HNE and the lack of its genetic association caused by alverine associated with anti-Lamin a and C autoantibodies. J Biol Chem. 2017;292(5):1378–87.

47. Lussiez V, Combe B, Graafland H, Rucheton M, Sany J. Anti-Sm and anti-RNP antibodies detected by immunoblotting in disseminated lupus erythematosus. Rev Rhum Mal Osteoartic. 1989;56(1):35–8.

48. Lussiez V, Combe B, Graafland H, Rucheton M, Sany J. Anti-Sm and anti-RNP antibodies detected by immunoblotting in disseminated lupus erythematosus. Rev Rhum Mal Osteoartic. 1989;56(1):35–8.

49. Preuss B, Berg C, Altenberend F, Gregor M, Stevanovic S, Klein R. Demonstration of autoantibodies in patients with unexplained infertility and premature ovarian failure. Fertil Steril. 2010;94(7):2041–46.

50. Fillit H, Shibata S, Sasaki T, Spera H, Kerr LD, Blake M. Autoantibodies to the protein core of vascular basement membrane heparan sulfate proteoglycan in systemic lupus erythematosus. Autoimmunity. 1993;14(3):243–45.

51. Kaburaki J, Stollar BD. Identification of human anti-DNA, anti-RNP, anti-SM, and anti-SS-A serum antibodies bearing the cross-reactive 16/6 idiotype. J Immunol. 1987;139(2):385–92.

52. Preuss B, Berg C, Altenberend F, Gregor M, Stevanovic S, Klein R. Demonstration of autoantibodies in patients with unexplained infertility and premature ovarian failure. Fertil Steril. 2010;94(7):2041–46.
66. Lehmeier T, Foulaki K, Luhmann R. Evidence for three distinct D proteins, which react differentially with anti-Sm autoantibodies, in the cores of the major snRNPs U1, U2, U4/U6 and US. Nucleic Acids Res. 1990;18(22):6475–84.

67. Mahesh SP, Li Z, Buggage R, Mor F, Cohen IR, Chew EY, Nussenblatt RB. Alpha tropomyosin as a self-antigen in patients with Behcet’s disease. Clin Exp Immunol. 2005;140(2):368–75.

68. Gajbiye R, Sonawani A, Khan S, Suryawanshi A, Kadam S, Warty N, Raut V, Khole V. Identification and validation of novel serum markers for early diagnosis of endometriosis. Hum Reprod. 2012;27(2):408–17.

69. Kimura A, Sakurai T, Yamada M, Kouruma A, Hayashi Y, Tanaka Y, Hozumi I, Ohnaki H, Chousa M, Takemura M, et al. Anti-endothelial cell antibodies in patients with cerebral small vessel disease. Curr Neurol Res. 2012;6(4):296–301.

70. Renaudeau Y, Dalekos GN, Gueguen P, Zachou K, Younou P. Anti-alpha-actinin antibodies cross-react with anti-sDNA antibodies in active autoimmune hepatitis. Clin Rev Allergy Immunol. 2008;34(3):321–5.

71. van Beers JJ, Willemze A, Stammen-Vogelzangs J, Drijfhout JW, Toes RE. Lehmeier T, Foulaki K, Luhrmann R. Evidence for three distinct D isoforms as major autoantigens in dilated cardiomyopathy. Circulation. 1992;85(5):1734–8.

72. Loeper J, Descatoire V, Maurice M, Beaune P, Belghiti J, Houssin D, Ballet F, van Beers JJ, Willemze A, Stammen-Vogelzangs J, Drijfhout JW, Toes RE. Evidence for three distinct D isoforms as major autoantigens in dilated cardiomyopathy. Circulation. 1992;85(5):1734–8.

73. Zhang et al. BMC Immunology 2019;20:21

74. Senecal JL, Rauch J, Grodzicky T, Raynauld JP, Uthman I, Nava A, Guimond C, Caforio AL, Grazzini M, Mann JM, Keeling PJ, Bottazzo GF, McKenna WJ, Schiaffino S. Identification of alpha- and beta-cardiac myosin heavy chain isoforms as major autoantigens in dilated cardiomyopathy. Circulation. 1992;85(5):1734–8.

75. Zhang et al. BMC Immunology 2019;20:21

76. van Beers JJ, Willemze A, Stammen-Vogelzangs J, Drijfhout JW, Toes RE. Evidence for three distinct D isoforms as major autoantigens in dilated cardiomyopathy. Circulation. 1992;85(5):1734–8.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.